AVTX Stock Forecast: Avalo Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Avalo Therapeutics, Inc. is $34. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Avalo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (70): The business earns solid, repeatable profits on what it owns.
Momentum (19): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AVTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AVTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Wedbush | Maintains | Outperform | $22 → $20 |
| 23 Oct 2026 | BTIG | Maintains | Buy | $58 → $10 |
| 23 Oct 2026 | Guggenheim | Downgrade | Neutral | — |
| 23 Oct 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 23 Oct 2026 | Wedbush | Maintains | Outperform | $34 → $22 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $50 → $48 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $35 → $30 |
| 6 July 2026 | Leerink Partners | Initiates | Outperform | $38 |
| 16 June 2026 | BTIG | Reiterates | Buy | — |
| 12 June 2026 | B of A Securities | Initiates | Buy | — |
| 14 May 2026 | Citizens | Maintains | Market Outperform | — |
| 14 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 May 2026 | Mizuho | Maintains | Outperform | — |
| 14 May 2026 | Wedbush | Maintains | Outperform | — |
| 11 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 6 May 2026 | BTIG | Maintains | Buy | — |
| 6 May 2026 | Citizens | Maintains | Market Outperform | — |
| 6 May 2026 | Wedbush | Maintains | Outperform | — |
| 13 Apr 2026 | BTIG | Reiterates | Buy | — |
| 9 Apr 2026 | Wolfe Research | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AVTX.
This page is one stock. Monday covers all of them.
AVTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AVTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Avalo Therapeutics, Inc. returned −61.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AVTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6625.2×
- Price / book
- 0.8×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- −33.6%
- Return on assets
- −19.7%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Avalo Therapeutics, Inc. has a market value of $390.3M.
Revenue in the twelve months to 30 June 2026: $59K.
Net income over the same four quarters: −$100.3M, a −170055.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$68.3M.
Avalo Therapeutics, Inc. employs 33 people — $2K of revenue per employee.
Data provided by Twelve Data
AVTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AVTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Avalo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AVTX
What is the AVTX stock price forecast for 2026-2027?
The median 12-month analyst price target for Avalo Therapeutics, Inc. is $34, with estimates ranging from $10 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AVTX stock a buy right now?
Of the 14 analysts covering Avalo Therapeutics, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalo Therapeutics, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AVTX?
As at 21 Nov 2026, Avalo Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (70 of 100).
Will AVTX stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts is $34, and Ticker Nerd's factor model ranks Avalo Therapeutics, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AVTX stock forecast for 2030?
No analyst covering Avalo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $60 over the next 12 months.
How has AVTX stock performed over the past year?
Avalo Therapeutics, Inc. returned -61.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Avalo Therapeutics, Inc. do?
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions. Avalo Therapeutics also maintains a pipeline that includes additional immune-focused programs, reflecting its emphasis on targeting dysregulated inflammation through biologic therapies. Based in Wayne, Pennsylvania, and incorporated in 2011, the company operates within the immunology and inflammation space, where its products are aimed at diseases with significant unmet medical need.
CEO Dr. Garry A. Neil M.D. · 33 employees · United States · https://www.avalotx.com